CYCN Cyclerion Therapeutics, Inc.
Price Chart
Executive Summary
Cyclerion Therapeutics files S-4/A for reverse merger with Korsana Biosciences. Current CYCN shareholders will own ~1.5% of the combined company, while Korsana holders (including a $380M pre-closing financing) will own ~98.5%. The combined company will focus on Korsana's preclinical Alzheimer's candidate KRSA-028. CYCN's existing cash of $3.2M is insufficient to continue as a going concern without the merger. Shareholders receive contingent value rights (CVRs) for legacy assets, which may be valueless.
Actionable Insight
Monitor shareholder vote on merger proposals and Nasdaq listing approval. CYCN stock may trade based on merger arbitrage dynamics; if merger fails, CYCN likely faces liquidation risk. CVRs provide potential but highly uncertain upside from legacy asset monetization.
Key Facts
- CYCN shareholders to own ~1.5% of combined company on fully-diluted basis vs. ~98.5% for Korsana holders
- Korsana raised ~$380M in pre-closing PIPE from top-tier healthcare investors
- CYCN has substantial doubt as a going concern with only $3.2M cash as of Dec 2025
- Combined company to focus on Korsana's preclinical anti-amyloid antibody KRSA-028 for Alzheimer's
- Shareholders receive CVRs for legacy assets with no guarantee of payment
- Reverse stock split required to meet Nasdaq listing minimum bid price
- Merger expected to close in Q3 2026; conditions include shareholder and Nasdaq approval
Financial Impact
Massive dilution for CYCN shareholders from ~100% to ~1.5% ownership; no financial figures provided for combined company revenue or earnings
Risk Factors
- Merger may not close if shareholder or Nasdaq conditions are not met
- CYCN shareholders face near-total dilution of economic interest
- CVRs may expire worthless if legacy assets are not monetized
- Combined company is preclinical with no approved products and requires significant additional capital
Market Snapshot
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-4/A Filing (Primary) | 0001193125-26-263731 |
| Document: d111069dex1028.htm | 0001193125-26-263731 |
| Document: d111069dex1034.htm | 0001193125-26-263731 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 9, 2026
3d ago
|
S-4/A
| $3.01 awaiting T+20 | awaiting T+20 | — | $3.25 (−7.97%) |
|
Apr 30, 2026
6w ago
|
10-K/A
| $3.31 $3.18 | ▼ −3.93% | ▼ −8.90% | $3.25 (−1.81%) |
|
Apr 1, 2026
10w ago
|
425
| $6.15 $3.31 | ▼ −46.18% | ▼ −56.06% | $3.25 (−47.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access